TIMI 15B

TIMI 15B evaluated the pharmacodynamic response, safety and pharmacokinetics of the GP IIb/IIIa inhibitor RPR 109891 given intravenously followed by oral administration for the treatment of patients with acute coronary syndromes.

timi-15b-slides

MAIN RESULTS:
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials
TIMI 15A & 15B
Am Heart J. 2000 Jul;140(1):81-93.

MAIN RESULTS PRESENTATION

TIMI 15b Main Results

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close